CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
Study Number | Lead Group | Study Title | CIRB | Study Status |
---|---|---|---|---|
NRG-HN004 | NRG | Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin | Adult CIRB - Late Phase Emphasis | Available to Open |
E5508 | ECOG | Randomized Phase III Study of Maintenance Therapy with Bevacizumab; Pemetrexed; or a Combination of Bevacizumab and Pemetrexed Following Carboplatin; Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC | Adult CIRB - Late Phase Emphasis | Available to Open |
A091603 | Alliance | A Randomized Phase II Trial of Adjuvant Nivolumab or Expectant Observation Following Neoadjuvant Ipilimumab Plus Nivolumab and Surgical Resection of High-Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma | Adult CIRB - Late Phase Emphasis | Completed |
S2207 | SWOG | Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapsed/Refractory Large B-Cell Lymphoma | Adult CIRB - Late Phase Emphasis | Available to Open |
NCCTG-N06C6 | NCCTG | A Phase III Randomized Trial of Cryoablation vs. Radiation for the Palliation of Painful Bone Metastases | Adult CIRB - Late Phase Emphasis | Completed |
EA6192 | ECOG-ACRIN | A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop) | Adult CIRB - Late Phase Emphasis | Available to Open |
SWOG-9007 | SWOG | Cytogenetic Studies in Leukemia Patients | Adult CIRB - Late Phase Emphasis | Completed |
CALGB-49808 | CALGB | A 2 X 2 X 2 Factorial Randomized Phase III Trial of Multimodality Therapy Comparing 4 Cycles of Doxorubicin and Cyclophosphamide with or without Dexrazoxane (AC +/- Z) Followed by 12 Weeks of Weekly Paclitaxel with or without Trastuzumab (T H) Followed by Local Therapy Followed by 40 Weeks of Weekly Trastuzumab or none in Women with HER-2+ STAGE IIIA; IIIB or Regional Stage IV Breast Cancer **ADMINISTRATIVELY COMPLETED as of December 15; 2002** | Adult CIRB - Late Phase Emphasis | Completed |
NRG-GY007 | NRG | A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian; Fallopian Tube; or Primary Peritoneal Cancer | Adult CIRB - Late Phase Emphasis | Available to Open |
RTOG-0522 | RTOG | A Randomized Phase III Trial of Concurrent Accelerated Radiation and Cisplatin Versus Concurrent Accelerated Radiation; Cisplatin and Cetuximab (C225) [Followed by Surgery for Selected Patients] For Stage III and IV Head and Neck Carcinomas<br> | Adult CIRB - Late Phase Emphasis | Completed |